Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Xenofon Baraliakos, EULAR 2022: Upadacitinib in the Treatment of Psoriatic Arthritis with Axial Involvement

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 24th 2022

Upadacitinib is an oral JAK1 inhibitor approved for the treatment of psoriatic arthritis. It was a pleasure to talk with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) about the impact of axial involvement on patients with psoriatic arthritis and the findings from his study investigating upadacitinib in the treatment of PsA with axial involvement.

The abstract ‘EFFICACY OF UPADACITINIB ON PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT DEFINED BY INVESTIGATOR ASSESSMENT AND PROBASED CRITERIA: RESULTS FROM TWO PHASE 3 STUDIES.’ (Abstract number: POS0934) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.

Questions

  1. What is the impact of axial involvement on patients with psoriatic arthritis (PsA)? (0:19)
  2. How is axial involvement identified in patients with PsA? (1:17)
  3. What was the rationale for, and design of, the post-hoc analysis you are presenting? (2:23)
  4. What were the findings of this analysis, and how do they compare with previous data? (3:13)
  5. What are the clinical implications of these findings? (4:31)

Disclosures: Xenofon Baraliakos discloses consulting for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving payment or honoraria for lectures from: Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving grant/ research support from Abbvie, Novartis and MSD; serving on advisory boards for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving honoraria from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; participating in speaker’s bureaus for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the EULAR meeting 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup